Home/Filings/4/0001209191-21-017555
4//SEC Filing

Gordon David N. 4

Accession 0001209191-21-017555

CIK 0001557746other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 8:42 PM ET

Size

19.4 KB

Accession

0001209191-21-017555

Insider Transaction Report

Form 4
Period: 2021-03-01
Gordon David N.
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2021-03-01+20,600108,135 total
  • Tax Payment

    Common Stock

    2021-03-01$24.06/sh5,660$136,180102,475 total
  • Exercise/Conversion

    Common Stock

    2021-03-02+8,297110,772 total
  • Tax Payment

    Common Stock

    2021-03-02$23.25/sh2,280$53,010108,492 total
  • Award

    Employee Stock Option (Right to Buy)

    2021-03-01+99,50099,500 total
    Exercise: $24.06Exp: 2031-02-28Common Stock (99,500 underlying)
  • Award

    Restricted stock units

    2021-03-01+28,40028,400 total
    Common Stock (28,400 underlying)
  • Exercise/Conversion

    Restricted stock units

    2021-03-0120,60041,200 total
    Common Stock (20,600 underlying)
  • Exercise/Conversion

    Restricted stock units

    2021-03-028,29724,892 total
    Common Stock (8,297 underlying)
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F2]The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
  • [F3]Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date.
  • [F4]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
  • [F5]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
  • [F6]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Issuer

Aclaris Therapeutics, Inc.

CIK 0001557746

Entity typeother

Related Parties

1
  • filerCIK 0001751167

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 8:42 PM ET
Size
19.4 KB